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Snake envenoming is a globally neglected public health problem. Antivenoms produced
using animal hyperimmune plasma remain the standard therapy for snakebites. Although
effective against systemic effects, conventional antivenoms have limited efficacy against
local tissue damage. In addition, potential hypersensitivity reactions, high costs for
animal maintenance, and difficulties in obtaining batch-to-batch homogeneity are
some of the factors that have motivated the search for innovative and improved
therapeutic products against such envenoming. In this study, we have developed a set of
nanobodies (recombinant single-domain antigen-binding fragments from camelid heavy
chain-only antibodies) against Bothrops atrox snake venom hemorrhagic and myotoxic
components. An immune library was constructed after immunizing a Lama glama with
whole venom of B. atrox, from which nanobodies were selected by phage display
using partially purified hemorrhagic and myotoxic proteins. Biopanning selections
retrieved 18 and eight different nanobodies against the hemorrhagic and the myotoxic
proteins, respectively. In vivo assays in mice showed that five nanobodies inhibited the
hemorrhagic activity of the proteins; three neutralized the hemorrhagic activity of whole
B. atrox venom, while four nanobodies inhibited the myotoxic protein. A mixture of the
anti-hemorrhagic and anti-myotoxic nanobodies neutralized the local tissue hemorrhage
and myonecrosis induced by the whole venom, although the nanobody mixture failed
to prevent the venom lethality. Nevertheless, our results demonstrate the efficacy and
usefulness of these nanobodies to neutralize important pathologies of the venom,
highlighting their potential as innovative therapeutic agents against envenoming by B.
atrox, a viperid species causing many casualties in South America.
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INTRODUCTION
Snakebite envenoming is an important public health problem
worldwide, especially in tropical and subtropical countries.
Around the world, 5 million snakebites occur each year, affecting
mainly the rural populations and causing an estimated 100,000
deaths (1). Victims that survive snake envenoming may suffer
from permanent physical sequelae, such as amputation of the
affected body parts, as well as psychological sequela, such
as depression, which can reduce their productive capacities
and affect normal life. Moreover, most snake envenoming
accidents in developing countries occur in remote areas, often
far away from health services, or where antivenoms are
unavailable, which decreases the chances for effective treatment
and lifesaving of the victims.
Venomous snakes around the world include the families
Viperidae, Elapidae, Atractaspididae, and Colubridae (2), the
former two being the most medically relevant. Within the
Viperidae family, the genus Bothrops is responsible for the most
snake envenoming in Central and South America, causing high
morbidity and mortality (3).
Antivenom administration is the only effective treatment for
snake envenoming. Currently, antivenom production is based
on the immunization of equines or ovine with snake venoms
according to the species responsible for the accidents in a
region or country.
Hyperimmune plasma is obtained and used for purification
of whole IgG antibodies (150 kDa) or for obtaining antibody
fragments, such as F(ab’)2 (100 kDa) or Fab (50 kDa), for the
antivenom formulation (4).
Besides conventional antibodies, camelids and some shark
species produce naturally a unique type of antibody that is
composed of heavy chains only, referred to as heavy-chain-
only antibodies (HCAbs) (5). The antigen recognition of
these functional HCAbs is comprised in the variable region
of their heavy chain [abbreviated as VHH and referred to
as Nanobody (Nb)].
Nanobodys are small proteins of approximately 15 kDa;
they are the smallest intact antigen-binding fragment (6) that
retains the specificity and affinity of the original HCAb in
recognizing the antigen (7, 8). The Nbs have promising potential
as therapeutic (9–11) and diagnostic tools (12). Their third
antigen-binding loop, or CDR3 (complementarity determining
region), is longer than that of VH domains of conventional
antibodies, and this prolonged loop interacts preferentially with
cavities or concave surfaces, such as the active site of enzymes
(13). While large clefts or grooves on the surface of antigens
are less likely to interact with the flat surface of the paratope
of classical antibodies, they are frequently observed to associate
with the convex paratope formed mainly by the CDR3 of camelid
VHHs (14). Furthermore, the substitution of conserved large
and hydrophobic amino acids in the framework-2 region of VH
with smaller and hydrophilic amino acids, prevents the Nbs from
associating with a VL domain like in classical antibodies. It also
renders the isolated Nb soluble in aqueous solutions without
any sign of aggregation (8). In addition, Nbs resist exposure
to elevated temperatures (15), and they are expressed to high
levels in microorganisms, such as E. coli, thereby reducing the
production cost.
Bothrops atrox snake venom has been characterized in
previous studies (16) including proteomic analysis, which have
determined the predominant presence of metalloproteinases of
the SVMP-I and SVMP-III classes in addition to other protein
types, such as phospholipase A2 (PLA2) and PLA2-like homologs,
serine proteinases, and disintegrins, among others (17).
SVMPs are relevant toxins of Bothrops spp. venoms since
many display a potent hemorrhagic effect, especially those of the
SVMP-III class (18, 19). On the other hand, basic PLA2 and
PLA2-like proteins induce a strong myotoxic effect leading to
local necrosis (20, 21). Together, these two types of toxins are
mainly responsible for the local tissue damage that may develop
in severe envenoming by Bothrops species (3).
Currently, there are few countries in Latin America that
produce antivenoms. In Peru, the National Institute of Health
produces a polyvalent antivenom in equines, which is the only
effective treatment against snake bites. The antivenom is obtained
after successive subcutaneous injection of equines every 8 days
with the venoms of several snake species. Blood is collected
after a period of 3 months and plasma is processed to obtain
the IgG fraction.
It has been calculated that probably less than 30% of the total
antibodies from an equine antivenom are effectively neutralizing
the toxins of the venom (22). Moreover, among important
potential adverse effects of the antivenoms produced in equines
are vasculitis, arthritis, and renal failure, which may originate
from the formation of immunocomplexes between antivenom
antibodies and the anti-horse antibodies that accumulate in blood
vessels, joints, and glomeruli (22).
There is an urgent need to reduce the costs and to increase
the efficiency of current antivenoms. In this context, many
researchers have proposed novel alternatives to the common
use of equine antibodies, such as recombinant antibodies from
human or camelid VHH (23).
In this study, we have constructed a camelid (Lama glama)
immune VHH library to retrieve Nbs against B. atrox venom
using a phage display strategy. Several Nbs directed against
hemorrhagic and myotoxic components were cloned and
recombinantly expressed in E. coli. Their ability to neutralize
hemorrhage and myotoxicity was screened in preincubation-type
assays in mice, to reveal their potential as eventual therapeutic
agents against snakebite envenoming, particularly against the
local tissue pathology induced by venom SVMPs and PLA2.
MATERIALS AND METHODS
Ethics Statement
Experiments involving animals were carried out in accordance
with recommendations of the National Council for the Control
of Animal Experimentation (CONCEA) and were approved by
the Ethics Committee on Animal Use from the National Institute
of Health from Perú under protocol IE003.
All mice were euthanized after experiments by CO2 inhalation.
A llama was immunized with sublethal doses of snake venom
Frontiers in Immunology | www.frontiersin.org 2 May 2020 | Volume 11 | Article 655
fimmu-11-00655 May 7, 2020 Time: 13:9 # 3
Bailon Calderon et al. Nanobodies Against Bothrops atrox Venom
according to previously reported doses for these animals,
and their health statuses were continuously monitored by a
veterinarian experienced in camelid management.
Partial Purification of Hemorrhagic and
Myotoxic Proteins of B. atrox Venom and
in vivo Activity Assays
The venom of B. atrox was obtained from many individual
snakes of the Peruvian region of Iquitos-Loreto. Venom was
pooled, lyophilized, and stored at −80◦C. A sample of 500 mg
was dissolved in 2 ml of 10 mM HEPES buffer, pH 7.5, as
this solution is accepted to keep the proteins in an active
conformation. The solubilized venom was applied to a Sephadex
G100 column previously equilibrated with the same buffer.
Fractions of 2 mL/tube were collected at a flow rate of 12 mL/h.
The protein peaks were monitored at 280 nm, collected, analyzed
by SDS-PAGE, and tested for toxic activities.
The hemorrhagic activity was determined by intradermal
injection in the ventral skin of mice (24), as described previously
(25). The myotoxic activity was evaluated through the release of
Creatine kinase (CK) to plasma (26). CK activity was determined
using a commercial kit CK-NAC∗FS (Diasys) and expressed as the
“minimum myotoxic dose” (MMD) (27). Tissue samples from the
mice were obtained for histological evaluation.
Immunization of Lama glama and
Immune Response Monitoring
A two-year-old adult male L. glama, provided with food and
water ad libitum, was immunized at weekly intervals for 10 weeks
with increasing doses of B. atrox venom (0.5, 1, 2, 3, and
6 × 4 mg), mixed with Gerbu adjuvant (Gerbu Biotechnic), at
a 1:1 ratio in 2 mL total volume of the inoculum. The mixture
of venom and adjuvant was administered via subcutaneous
injections in four nearby sites of the loin of the llama. After a
waiting period, several additional injections were administered,
as indicated in Figure 1.
The immune response of the llama was monitored by an
enzyme linked immunosorbent assay (ELISA). Briefly, microtiter
plates (Thermo Fisher Scientific) were coated with 50 ng
of B. atrox whole venom diluted in 15 mM Na2CO3 and
35 mM NaHCO3, and incubated overnight at 4◦C. Wells
were washed with washing buffer (PBS; 0.05% Tween-20),
and residual protein binding sites on the plastic were blocked
with blocking solution (either 1% BSA or 2% skim milk in
PBS) for 1 h at room temperature. Then, serial dilutions
(1:50; 1:100;1:200; 1:400; 1:800; 1:1600, and 1:3200) of the
llama serum, collected each week, as well as pre-immune
serum, were added to the wells and the plates were incubated
for 1 h at room temperature. The plate was washed five
times, and goat anti-llama IgG-peroxidase conjugate (Thermo
Fisher Scientific) at a 1:12000 dilution in blocking solution
was added to each well and incubated for 1 h. The wells
were washed again and finally, 100 µL TMB/H2O2 substrate
(Invitrogen) was added to the wells. After 5–15 min incubation
at room temperature and shielded from light, we added
50 µL of 0.5 M H2SO4 to stop the color reaction and
absorbances were measured at 450 nm in a microplate reader
(Multiskan Go, Thermo Fisher Scientific). Each sample was
run in triplicate, and the pre-immune serum was used as
negative control.
Nanobody Library Construction
Llama whole blood (150 mL) was collected by venipuncture
3 days after the last immunization. Lymphocytes were isolated
by centrifugation over a gradient of Ficoll-Paque Plus (GE
Healthcare). Total RNA from the lymphocytes was extracted
with Trizol Reagent (Invitrogen), purified by RNA Mini kit
(Qiagen). The cDNA was synthesized by Superscript III Reverse
Transcriptase (Invitrogen), and the first PCR with CALL001 and
CALL002 primers was carried out. PCR products of around
700 and 900 bp were obtained, and the band of 700 bp was
purified from agarose gel. This PCR product was used as the
template for a second, nested PCR with specific primers carrying
a recognition sequence for SapI restriction enzyme at both
5′ ends, amplifying a product of about 500 bp corresponding
to the VHH gene, which was purified by phenol/chloroform.
The Restriction/Ligation reaction was set up in a single tube
containing 1 µg of the pMECS-GG phagemid vector, 3 µg of
VHH PCR product, 250 U of SapI enzyme, 2.5 µl T4 DNA
Ligase (15 U), 5 µl of 10 mM ATP, and 10 µl of reaction buffer,
in a final volume of 100 µl. The pMECS vector encodes an
influenza virus Haemagglutinin tag (HA) used for immunoassay
selection and a 6x-His tag used for affinity purification of the
expressed nanobody.
Enrichment of Target-Specific VHH by
Phage Display Biopanning
A representative aliquot of the Nb library was cultured in 330 mL
2xTY medium (supplemented with 100 µg/mL ampicillin, 2%
glucose) at 37◦C until the exponential growth phase was reached,
infected with M13 helper phages, and incubated overnight at
37◦C with continuous shaking. The bacteria were pelleted by
centrifugation, and phage particles were recovered from the
supernatant by precipitation with a concentrated polyethylene
glycol solution (20% PEG and 2.5 M NaCl). Precipitated phage
particles were resuspended in 1 mL PBS and quantified by
spectrophotometry.
Two partially purified antigens of B. atrox venom with
different enzymatic activities were used separately to select
specific Nbs. A well of an ELISA plate was coated with antigen
(15, 10, and 5 µg in the first, second, and third round of
biopanning, respectively) in 0.1 M NaHCO3 buffer, pH 8.2.
The plate was incubated overnight at 4◦C, and residual protein
binding sites were blocked with 2% skim milk for 2 h at room
temperature. Then, 1 × 1011 phage particles were added and
incubated for 30 min without shaking. After few washings,
antigen-binding phages were eluted with 100 µl of freshly
prepared triethylamine 100 mM, incubated for only 5 min at
room temperature, and neutralized with 1.0 M Tris–HCl (pH
7.4). The phage particles were used to infect a fresh E.coli culture
and used to initiate the next round of panning or spread on Petri
dishes for titration.
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FIGURE 1 | Immune response of llama against B. atrox snake venom and neutralization potency of hyperimmune serum. The venom protein-specific antibodies
within the sera (diluted 3200 times) was evaluated using 50 ng of total B. atrox venom in an ELISA (black line). The open upward pointing arrows show the days that
the llama was immunized and the black downward pointing arrow shows the time of bleeding to generate the Nb library. The neutralization potency of these serum
antibodies against the lethal effect of the venom was also determined in mice (red line).
Selection of Clones, Expression, and
Purification of Recombinant Nanobodies
Individual colonies were grown after the first or second round
of panning, and the periplasmic extracts were obtained for the
identification of clones with antigen-specific Nbs. An ELISA was
carried out by coating with 2 µg/mL of antigen used in each
biopanning (for each clone we foresee a well coated with and
a well without the target protein). Incubation was carried out
overnight at 4◦C. After removal of excess antigen and washing the
wells thee times with washing buffer (0.05% Tween 20 in PBS), we
added 200 µl of blocking solution (2% BSA in PBS). Incubation
was carried out for 2 h at room temperature. After removing the
blocking solution and washing the wells five times with washing
buffer, 100 µl of a 1/2 dilution in PBS of each periplasmic extract
was added to the wells and incubated for 1 h at room temperature.
Then, the cell extracts were removed, wells were washed five
times with washing buffer, and 100 µl of a 1/2000 dilution of
mouse primary antibody against the hemagglutinin tag was added
and incubated for 1 h at room temperature. After washing the
wells eight times, 100 µl of a 1/2000 dilution of anti-mouse IgG
secondary antibody conjugated with Alkaline Phosphatase (Cell
Signaling) was added. Incubation was carrued for 1 h at room
temperature, followed by removal of unreacted antibody, eight
washes with washing buffer, and, finally, the addition of 100 µl
of the substrate solution for alkaline phosphatase. Absorbances
were measured at 405 nm. The positive clones were identified
when the absorbance value in wells with target protein was at least
three times above the value of the signal in control wells lacking
antigen. For all ELISA positive clones, we performed a colony
PCR using the Nova Taq PCR Master Mix kit (Merck Millipore)
to verify the insert size. Finally, the nucleotide sequencing of
each clone was performed using the Applied Biosystems 3500 XL
genetic analyzer.
Each ELISA positive clone (in TG1 cells) with a unique
sequence was cultured, and a plasmid preparation was used to
transform chemically competent WK6 E. coli cells. Recombinant
WK6 clones were analyzed by colony PCR and DNA sequencing
of their VHH gene to confirm that their DNA sequence was
identical to that obtained for TG1 clones.
Unique clones were grown in 1 L of TB medium while shaking
at 37◦C to reach an OD at 600 nm of 0.6–0.9, before adding 1/100
volume 1 M IPTG and continue culturing for 14–16 h at 28◦C.
The bacteria were harvested by centrifugation, and cell pellets
were resuspended in TES solution (Tris, EDTA, Sucrose). The
tubes with the cell suspension were shaken at 200 rpm for 6 h
at 4◦C, then 2 volumes of TES/4 were added, and the shaking was
continued overnight in the cold room. Finally, unique Nb extracts
were purified on Ni2+ resin His60 Superflow. The captured his-
tagged Nb was eluted from the Ni2+ resin with 500 mM imidazole
in PBS. The Nb eluate was depleted of imidazole by diluting and
concentrating by centrifugal ultrafiltration. The concentration of
the purified Nb protein was determined by the Bradford method.
Neutralization of the Hemorrhagic and
Myotoxic Activity by Nanobodies
A first anti-hemorrhagic screening assay was performed by
challenging groups of three mice intradermally with a quantity
of the hemorrhagic protein (1.4 µg) known to produce sufficient
Frontiers in Immunology | www.frontiersin.org 4 May 2020 | Volume 11 | Article 655
fimmu-11-00655 May 7, 2020 Time: 13:9 # 5
Bailon Calderon et al. Nanobodies Against Bothrops atrox Venom
FIGURE 2 | SDS-PAGE (15% acrylamide) of the hemorrhagic and myotoxic
fractions from Bothrops atrox snake venom. L, protein ladder (Thermo Fisher
Scientific #26623) with molecular masses in kDa at the left-hand side of the
figure. V, B. atrox whole venom; Mtx: fraction with myotoxic activity; Htx,
fraction with hemorrhagic activity.
hemorrhagic activity either alone or pre-incubated with 90 µg of
each purified Nb for 1 h at 37◦C.
In a second neutralization assay, the minimum hemorrhagic
dose (MHD) of B. atrox whole venom was determined, and a
challenge of 5 MHD of venom alone, or preincubated with the
different Nbs, was tested in mice by intradermal injection. Free
image analysis software (Inkscape 0.91) was used to determine
the size of the area and intensity of hemorrhagic lesion (28).
For the neutralization test of myotoxic activity, 3 MMD
(minimum myotoxic dose) was used as challenge (13.5 µg), in
groups of six mice. The venom was preincubated with 40–70 µg
of each purified Nb for 1 h at 37◦C, and then 100 µl of the
mixture was injected intramuscularly. Control mice received the
same dose of venom preincubated with PBS, or a PBS injection
alone. After 3 h, a blood sample was obtained from mice and the
Creatine Kinase (CK) activity in plasma was determined.
Neutralization of the Lethal Effect of
B. atrox Venom in Mice by a Mixture of
Nanobodies
Neutralization of the lethal effect of the venom was tested with a
challenge dose of 4 LD50 (median lethal dose), equivalent to 16 µg
intraperitoneally injected venom (LD50 = 3.96 µg). The venom
was preincubated with a pool of 100 µg of each of four selected
Nbs (H6, H8, H9, and M85) for 1 h at 37◦C, and then 0.5 mL of
the mixture was injected intraperitoneally in groups of six mice.
Control mice received PBS alone or venom preincubated with
PBS. The number of death mice was scored over a total time
of 48 h. At the end of this 48 h, all dead and living mice were
examined for hemorrhage of the peritoneal cavity.
RESULTS
Partial Purification of Hemorrhagic and
Myotoxic Proteins of B. atrox Venom and
in vivo Activity Assays
Bothrops atrox venom proteins were fractionated by size
exclusion chromatography and tested for hemorrhagic or
myotoxic activity in mice. Hemorrhagic activity was detected
in fractions 11–14, with fractions 13 and 14 showing 1.213 and
1.115 units (mm2/µg), calculated as the area of the hemorrhagic
lesion divided by the protein concentration of the toxin. Of these,
fraction 13 was selected for further assays because of its higher
hemorrhagic activity. It showed a predominant protein band of
50 kDa after SDS-PAGE (Figure 2).
On the other hand, a high myotoxic activity was detected
in fraction 18, showing two protein bands of 13 kDa and
23 kDa after SDS-PAGE (Figure 2), which correspond to the
monomeric and dimeric forms of a phospholipase A2-like
(Lys49) myotoxin. This was inferred by observing that the
myotoxic fraction showed no detectable phospholipase activity
on egg yolk phospholipids, nor anticoagulant effect on plasma,
when up to 100 µg were assayed.
The intramuscular injection of aliquots of fraction 18
induced a clear myotoxic effect in vivo, evidenced by the
increase of Creatine kinase activity in the plasma of treated
mice, reaching a maximum at 3 h and returning to normal
levels after 12 h. The minimal myotoxic dose (MMD) of
this protein was calculated to be 4.5 µg. It induced a CK
activity of 1891.7 U/L, compared to 192.1 U/L for plasma
of a PBS-injected mice. Histological examination of the
injected gastrocnemius muscle showed necrosis, edema, and
inflammatory infiltrate.
Llama Immune Response and
Neutralization of B. atrox Whole Snake
Venom by the Immune Serum
Immunization of a llama with B. atrox venom initially consisted
of only nine doses. Enzyme-immunoassay monitoring of
sera taken before each injection showed a rapid increase
of the total amount of venom-specific antibodies in the
serum (Figure 1). Three injections at weekly intervals were
sufficient to reach a plateau signal for the antigen-specific
antibodies within the serum diluted 3200 times, using
only 50 ng of total venom containing multiple proteins at
various concentrations.
However, despite this rapid antibody response, the
neutralization potency of the immune serum against a lethal
dose of B. atrox venom remained rather poor (0.78 mg/mL) after
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FIGURE 3 | Amino acid sequences and SDS-PAGE of selected nanobodies against the hemorrhagic fraction of B. atrox venom. Upper panel: Selected nanobody
sequences were grouped by CDR3. Framework Regions (FR); Complementarity-determining regions (CDR1, CDR2, and CDR3); amino acids highlighted in green are
some variations in the consensus FR sequences. Lower panel: SDS-PAGE (10% acrylamide) of selected nanobodies. Molecular mass markers (in kDa) are shown in
the first lane.
FIGURE 4 | Amino acid sequences and SDS-PAGE of selected nanobodies against the myotoxic fraction of B. atrox venom. Selected nanobody sequences (top)
were grouped by CDR3. Framework Regions (FR); Complementarity-determining regions (CDR1, CDR2, and CDR3). SDS-PAGE (15% acrylamide) of selected
nanobodies (bottom). Molecular mass markers (in kDa) are shown in the first lane.
nine injections of venom, compared to the minimum required
neutralization potency of Peruvian anti-bothropic antivenom
produced in equines (2.5 mg/mL).
Therefore, it was decided to perform additional
immunizations in an attempt to increase the neutralization
potency of the llama serum. This appeared to be successful
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as the neutralization potency increased to 3.6 mg/mL, a
level even higher than that obtained with equine antivenom
(2.5 mg/mL) (Figure 2).
Construction of a Llama Immune VHH
Library
After immunization of the llama with B. atrox venom, we isolated
about 5 × 106 lymphocytes from peripheral blood, to extract
total RNA that was reverse transcribed into cDNA, and used as
template to amplify the VHH genes in a two-step nested PCR.
The final VHH PCR amplicon was successfully ligated in pMECS-
GG phage display vector and transformed in TG1 E. coli cells.
We obtained a library of 1.78 × 109 clones that was used for
selection of Nbs.
Phage Display Selection of Recombinant
Nanobodies Against Hemorrhagic and
Myotoxic Proteins
A total of 94 clones were picked, separately, after the first
and second round of biopanning for screening against the
two antigen fractions by ELISA. Eighty clones expressed a Nb
that recognized the hemorrhagic protein, whereas 76 clones
recognized the myotoxin.
Colony PCR with VHH specific primers was performed on all
clones that scored positive in ELISA, and the DNA amplicons
were sequenced by the Sanger method and translated to amino
acid sequences. As expected, the VHH sequences showed a high
degree of redundancy, especially among the clones from the
second round of panning.
The complementarity determining regions (CDRs) and
framework regions (FRs) of VHH were identified for 18 and
8 unique Nb clones against the hemorrhagic and myotoxic
proteins, respectively. Based on their CDR3 sequences, these
sequences were grouped into 13 clusters or families for the
hemorrhagic protein and eight clusters for the myotoxic protein
(Figures 3, 4). Differences among clones from the same family
were located in FRs and CDRs as well.
Expression and Purification of VHH
The plasmid DNA of one clone from each cluster, and against
each of the two antigens, was transformed in WK6 E. coli cells
and was cultured in 1 L in order to express the encoded Nb in
the periplasm. The periplasmic protein extract was purified on
nickel-ion containing resin, eluted with 500 mM imidazole and
analyzed by SDS-PAGE.
The different nanobodies were obtained at variable yields,
between 0.5 to 5 mg of purified recombinant nanobody per
liter of culture. The vast majority of them revealed a single
band corresponding to the MW predicted from its amino acid
sequence (Figures 3, 4).
Neutralization of Hemorrhagic Activity by
Nanobodies
A first screening assay revealed five hemorrhage-neutralizing Nbs
(named H6, H7, H8, H9, H19, H46, and H78) which completely
inhibited the hemorrhagic activity of the venom fraction, whilst
some other Nbs neutralized it to a lower degree. When Nbs were
tested against the whole venom, three of them (H6, H8, and H9)
were able to fully neutralize the hemorrhagic activity (Figure 5).
FIGURE 5 | Screening of individual nanobodies against a hemorrhagic fraction of B. atrox venom to neutralize hemorrhagic activity in mice. Each nanobody (90 µg)
was mixed with 1.4 µg of the hemorrhagic protein and incubated for 1 h at 37◦C. Then, 100 µL of the mixture was injected intradermally in mice. After 3 h, mice
were euthanized, and the internal hemorrhagic areas of the skin were recorded. C+, mice injected with hemorrhagic fraction alone; C–, mice injected with PBS. The
group of nanobodies shown at the left did not neutralize hemorrhage, while the group at the right did.
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The neutralization potency of the Nbs was concentration-
dependent.
Selected Nbs neutralized the hemorrhagic activity with some
of them exhibiting somewhat different patterns of inhibition.
For example, Nbs H6 and H8 left a few localized hemorrhagic
spots even at the highest dose tested (92 µg Nb), whereas Nb
H9 resulted in a diffuse pattern of residual hemorrhage, which
disappeared with a dose of 92 µg Nb (Figure 6).
Inhibition of Myotoxic Effect of Whole
B. atrox Snake Venom
Six out of the eight myotoxin-specific Nbs were able to decrease
myonecrosis induced by the whole venom, as evaluated by the
CK activity levels in plasma. These Nbs were M28, M35, M43,
M67, M85, and M88, which blocked 40 to 63% of the myotoxic
activity of a 3 fold minimum myotoxic dose (3 MMD) challenge
with whole venom (Figure 7).
Neutralization of the Lethal Effect of
B. atrox Venom in Mice by a Mixture of
Nanobodies
Nanobodies (H6, H8, H9, and M85) that neutralized the
hemorrhagic and myotoxic activities of the venom fractions
were mixed and tested for the possible neutralization of the
lethal effect of the whole venom. However, this Nb cocktail was
unable to prevent lethality. Nevertheless, an examination of the
peritoneal cavity of the animals revealed that the widespread
hemorrhage caused by the venom in the control group was
effectively prevented by the Nb mixture (Figure 8).
DISCUSSION
Two main tissue-damaging components of B. atrox venom,
with hemorrhagic and myotoxic effects, respectively, were
used as antigens to select a set of Nbs from an immune
llama library by a phage-display enrichment. The hemorrhagic
fraction obtained likely corresponds to a PIII metalloproteinase
(SVMP III) reported to be the most hemorrhagic toxin of
this venom, with a molecular mass of 50 kDa, in agreement
with the main band observed in SDS-PAGE. Moreover, the
hemorrhagic activity analysis of B. atrox venom chromatographic
fractions showed two peaks, consistent with the presence of two
distinct metalloproteases (17), a highly active SVMP-III and a
weaker SVMP-I. These hemorrhagic proteins represented the
most abundant proteins in a proteomic study on the venom
composition, accounting for nearly 70% of the total protein
contents of the B. atrox venom (17).
On the other hand, the myotoxic protein fraction showed
biochemical and functional features that are consistent with
those of the previously reported Myotoxin I of B. atrox, a PLA2
homolog of the Lys49 type (29), devoid of catalytic activity. This
type of PLA2-like myotoxin is highly conserved within the genus
Bothrops, and found in many crotalid snake venoms of both Old
and New World species (30).
In order to obtain Nbs against relevant tissue-damaging
components of B. atrox venom, a llama was immunized following
an initial scheme of nine injections at weekly intervals. In spite
of the positive serum antibody response, neutralization potency
remained low, and therefore immunization was continued with
seven additional boosts with the venom. This resulted in an
FIGURE 6 | Neutralization of the hemorrhagic effect of whole B. atrox venom by nanobodies. Each nanobody (amounts indicated in µg in the legend at the left) was
mixed with 5 fold minimum hemorrhagic dose (5 MHD) of venom and incubated for 1 h at 37◦C. Then, 100 µL of the mixture was injected intradermally in mice. After
3 h, mice were euthanized, and the internal hemorrhagic areas of the skin were recorded.
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FIGURE 7 | Neutralization activity of individual Nbs on the myotoxic effect induced by a B. atrox venom fraction. Each Nb was mixed with 3 fold minimum myotoxic
dose (3 MMD) of protein (13.5 µg) and incubated for 1 h at 37◦C. Then, 100 µL of the mixture was injected intramuscularly in mice. After 3 h, the plasma Creatine
kinase activity was determined. C– and C+ represent the values for mice injected with PBS or venom alone, respectively. Bars represent mean ± SD of four mice.
FIGURE 8 | Neutralization of the hemorrhagic effect of whole B. atrox snake venom by a mixture of nanobodies. Venom alone (4 LD50) or preincubated with a
mixture of nanobodies for 1 h at 37◦C, was injected intraperitoneally in mice. Lethality was not prevented, but the widespread hemorrhage induced by the venom
was completely inhibited by the nanobody mixture.
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increase of the venom neutralization potency of the anti-
serum, conveniently explained by the affinity maturation of the
antibodies for their cognate antigens, compared to the first,
rapidly raised antibody population.
From the pool of Nb genes of the immunized llama, a set of
Nbs were obtained against the hemorrhagic or myotoxic venom
fractions, respectively. The Nbs showed great diversity, evidenced
by the number of different sequences obtained after one and two
rounds of panning. These nanobodies were grouped into several
clusters based on sequence identity in their CDR3, the region of
VHH with the largest variability.
Selected clones from each cluster were expressed in E. coli and
purified from cultures at a 1 L scale, with variable yields. SDS-
PAGE analysis of these Nbs showed a slight variation in molecular
weight that was in agreement with the Nb nucleotide sequences
and translation into amino acid sequences.
We then searched for Nbs capable of neutralizing two of the
most important pathological effects of B. atrox venom, namely
hemorrhage and myotoxicity. From the 18 and 8 Nbs obtained
against the hemorrhagic and myotoxic fractions, respectively,
several displayed neutralizing activity.
We identified Nbs H6, H8, and H9 to possess the best
neutralizing activity for the hemorrhagic effect of the snake
venom, and Nbs M28, M35, M43, M67, M85, and M88 as good
inhibitors of the myotoxic effect, albeit with some variations in
their neutralizing capacity.
It is important to consider that Nb clones of very
similar sequence, even in their CDR3 region, but having
one or more mutations in other regions such as CDR1
or CDR2, may have different neutralization capacity due
to differences in affinity for their target. Interestingly,
one of the Nbs with the shortest CDR3 region (H9)
was the best neutralizer of the hemorrhagic activity of
the whole venom.
Three of the Nbs were able to neutralize the hemorrhagic
activity of the whole venom, suggesting that they should inhibit
the activity of both the high molecular weight SVMP-III toxins
and the smaller SVMP-I. An alternative interpretation is that
the SVMP-III component plays a more predominant role in
the hemorrhagic effect of the whole venom, in comparison
to the SVMP-I, generally known to be of weaker activity
(31). Addressing the fine specificity of the toxins and epitopes
recognized by these Nbs, in future studies, will shed light on the
detailed mechanisms of neutralization.
Some of the obtained Nbs neutralized effectively local
pathological effects of venom toxins, such as bleeding and muscle
damage, and a mixture of them prevented the hemorrhagic
action of the whole venom. However, the neutralizing Nbs
were unable to prevent the lethal effect of the venom. This
is an interesting observation, which suggests that the lethal
action of the venom in this mouse model most likely involves
the participation of additional toxins, for example, enzymes
and non-enzymatic proteins that may affect hemostasis causing
thrombosis, platelet alterations, or inducing acute kidney damage
and hypotensive actions (32). Further studies should focus
on the identification of Nbs against additional components
of B. atrox venom having systemic toxicity involved in
the lethal effect.
In this study, we have tested the neutralizing ability of Nbs
in preincubation-type assays, as a first indicator of Nbs for
their potential as future therapeutic agents against snakebites.
Nbs to snake venoms have been obtained with this purpose
in previous studies (33, 34), and there are wide possibilities
of engineering a variety of molecular formats based on these
antigen-specific structures (22, 35–37). Future work on the
Nbs described here will address their preclinical neutralizing
performance when administered after envenoming, as well
as their potential for enhancing the neutralizing potency of
current therapeutic antivenoms against snake venom-induced
local tissue damage.
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